Overview

Adult RSV vaccination decisions involve both when a dose was given and what product evidence exists. In a two-season hospitalized study among adults aged 60 years or older, effectiveness was estimated at 69% for same-season vaccination and 48% for prior-season vaccination, but the difference was not statistically significant (P=.06), so it signals possible waning without establishing annual waning or a booster interval. Arexvy and Abrysvo had similar hospitalization estimates (64% and 61%; P=.73), while mResvia had too few recipients for an estimate. CDC has no preference among licensed and available vaccines; late summer or early fall is preferred, coadministration is allowed, and practical access and limited data still matter.

Learning outcomes

Same-season effectiveness was estimated at 69% versus 48% after prior-season vaccination, but P=.06 did not establish a significant difference or a fixed waning schedule.
Arexvy and Abrysvo had similar observed hospitalization effectiveness (64% vs 61%; P=.73); mResvia had too little uptake for an estimate.
CDC prefers late-summer or early-fall delivery but allows vaccination anytime, and coadministration decisions should consider limited data, access, exposure, and preference.

Keywords

RSVTimingDurabilityArexvyAbrysvomResvia

What Time and Product Change—and What They Do Not

Adult RSV vaccination now has a time problem as well as an eligibility problem. The key evidence question is whether protection differs when a dose is received in the same season as illness or in the prior season, and whether product or virus-subtype differences justify choosing one vaccine over another. A careful answer helps readers recognize a possible waning signal without turning it into an annual rule or mistaking an evidence gap for evidence of poor performance.

A lower later estimate is a signal, not a schedule

In the two-season hospitalization study, estimated vaccine effectiveness was 69% when vaccination occurred in the same RSV season as illness onset. The 95% confidence interval was 52% to 81%. When vaccination had occurred in the prior season, the estimate was 48%, with a confidence interval of 27% to 63%. The direction is what a reader might expect if protection diminishes with time: the point estimate was higher closer to the season of illness and lower after a longer interval.

But the statistical comparison did not establish a significant difference. The reported P value was .06, just above the conventional threshold used in the study. That does not prove that the two estimates are equal. It means the available data did not provide enough evidence to rule out chance or other differences as explanations for the observed gap. A point estimate can be directionally informative without being precise enough to set policy by itself.

The same caution applies to adults aged 75 years or older. Their estimated effectiveness was 81% with same-season vaccination and 59% with prior-season vaccination, but that comparison also did not meet conventional statistical significance. When time since vaccination was divided into 14–179 days and at least 180 days, the estimates showed a similar pattern. That consistency keeps waning on the research agenda, but it still does not reveal a precise curve showing exactly how much protection is lost on each date.

There are several reasons a same-season and prior-season comparison is not a clean stopwatch. People vaccinated in different seasons may differ in health, healthcare access, exposure, or willingness to seek vaccination. The circulating viruses and the intensity of RSV activity can change between seasons. The study also had limited sample size for some subgroup-by-time comparisons. An observational comparison can detect a pattern that is compatible with waning while leaving its size and cause uncertain.

The most accurate conclusion is therefore layered. One dose was associated with protection against hospitalization across two seasons. The point estimates were lower when vaccination occurred in the prior season, which is a reason to continue monitoring duration. The study did not establish that protection ends after one season, did not establish an annual decline of a fixed size, and did not identify the date at which a repeat dose becomes necessary.

Why “not annual” matters

A possible decline over time naturally leads to a practical question: should an adult receive another dose every year? Current CDC guidance says no. RSV vaccination is not currently an annual vaccine, and people who have received one dose have completed their vaccination for now.

Published by DeepMox

FAQ

Does a lower prior-season estimate prove RSV protection has ended?

No. The prior-season estimate was lower than the same-season estimate, but the difference was not statistically significant, and the study did not establish when protection becomes inadequate or a repeat dose becomes necessary.

When is the best time to receive an adult RSV vaccine?

Eligible adults can receive an RSV vaccine at any time, but late summer or early fall—generally August through October in most of the continental United States—is preferred so protection precedes usual RSV spread.

What does the two-season study show about Arexvy, Abrysvo, and mResvia?

It estimated similar hospitalization effectiveness for Arexvy (64%) and Abrysvo (61%), but too few mResvia recipients were included to estimate its effectiveness. The comparison did not prove complete equivalence or establish a product ranking.

Previous12 minAdult RSV Vaccination: Subgroup Protection

Next10 minAdult RSV Vaccination Safety Signals

Adult RSV Vaccination: Timing and Products

What Time and Product Change—and What They Do Not

A lower later estimate is a signal, not a schedule

Why “not annual” matters

FAQ